Werewolf Therapeutics

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

At Werewolf Therapeutics, we are passionate about transforming the landscape of cancer treatment through immune system activation. Our mission is to develop therapies that combine the power of the immune system with the precision of modern medicine to give hope to those battling cancer.

We believe that powerful and safe cancer treatments can be realized through eliciting the body’s own immune system. Our vision is a world where every person has access to oncotherapeutic treatments that are tailored to their individual immunological profile. This will enable us to outsmart cancer through an optimal combination of biology and medicine.

Werewolf Therapeutics has won numerous awards in the biotech field, including multiple from the Society of Biotechnology, Pharmaceuticals and Clinical Research, to support their innovative research into cancer treatments and therapeutics.